drugset / Trial / NCT01129180
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Phase 1
Completed
8 enrolled
Pierluigi Porcu
Celgene Corporation · collabMillennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Bortezomib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with azacitidine in treating patients with relapsed or refractory T-cell lymphoma.
Timeline
- Start
- 2010-05
- Primary completion
- 2012-05
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Subcutaneous |
| Subject | Bortezomib | Small molecule | — | Intravenous |
Indications
T-cell large granular lymphocyte leukemia
adult T-cell leukemia/lymphoma
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
extranodal nasal NK/T cell lymphoma
hepatosplenic T-cell lymphoma
mycosis fungoides and variants
peripheral T-cell lymphoma, not otherwise specified
post-transplant lymphoproliferative disease
prolymphocytic leukemia
small intestine lymphoma